Welcome to our dedicated page for GENETHERA news (Ticker: GTHR), a resource for investors and traders seeking the latest updates and insights on GENETHERA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GENETHERA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GENETHERA's position in the market.
GeneThera, Inc. (OTCMKT: GTHR) announced an exclusive partnership with Cushman & Wakefield (NYSE:CWK) to locate land and warehouse sites in Denver for the development of its Zoonotic Disease Alert Shield (ZIDAS) surveillance network. The initial focus will be on assembling Mobile Laboratory Units while a stationary BSL3 laboratory is being established. The ZIDAS network aims to detect asymptomatic carriers and emerging variants of SARS-CoV-2, highlighting the urgency of effective surveillance due to the Delta variant's spread.
GeneThera has established a new subsidiary in the UK, GeneThera Robotics Ltd, to manage UK and international operations. This move supports the development of the Zoonotic Infectious Diseases Alert Shield (ZIDAS) network, utilizing advanced Molecular Robotic and AI technology. The subsidiary will implement a dual laboratory system for high-throughput assays and wastewater testing for SARS-CoV-2. CEO Dr. Tony Milici emphasized the UK's promising market, particularly for detecting the B.1.1.7 variant. Mrs. Alex Baglietto has been appointed Managing Director, bringing extensive experience in government relations.
GeneThera has partnered with Cumming Corporation to establish a global network of laboratories focused on preventing and treating zoonotic diseases. This collaboration aims to enhance laboratory designs in response to lessons learned from the COVID-19 pandemic. The new facilities will include areas for genome sequencing, AI diagnostics, and biosafety level 3 viral growth, supporting the Zoonotic Diseases Alert Shield System (ZIDAS). The partnership is expected to accelerate GeneThera's expansion in the diagnostics and therapeutics of zoonotic diseases.
GeneThera is launching a global zoonotic infectious diseases alert shield (ZIDAS) to manage COVID-19 and prevent future pandemics. This initiative includes stationary integrated robotic lab facilities with ultra-high throughput capabilities, processing 100,000-200,000 samples daily, and mobile lab units capable of handling 2,000-4,000 samples per day. CEO Dr. Tony Milici emphasizes the significance of Smart Testing Technology (STT) in accurate virus detection and combating misinformation that leads to decreased testing. The goal is to deploy tens of thousands of mobile lab units worldwide.
GeneThera is addressing the challenges posed by the COVID-19 pandemic through advanced wastewater testing to monitor SARS-CoV-2 and asymptomatic carriers. Their technology, the Molecular Robotic/Artificial Intelligence Platform (MORAP), allows for the efficient processing of samples, providing timely epidemiological data. CEO Dr. Tony Milici emphasizes the importance of a nationwide wastewater surveillance program to reduce reliance on lockdown measures and obtain clearer insights into vaccine efficacy and public health intervention success.
FAQ
What is the market cap of GENETHERA (GTHR)?
